TSE:CPH FY2025 EPS Forecast Reduced by Leede Financial

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) – Analysts at Leede Financial reduced their FY2025 EPS estimates for Cipher Pharmaceuticals in a research report issued to clients and investors on Friday, November 8th. Leede Financial analyst D. Loe now anticipates that the company will post earnings per share of $0.93 for the year, down from their prior forecast of $1.02. Leede Financial has a “Hold” rating on the stock. The consensus estimate for Cipher Pharmaceuticals’ current full-year earnings is $1.29 per share. Leede Financial also issued estimates for Cipher Pharmaceuticals’ FY2026 earnings at $1.05 EPS and FY2027 earnings at $1.14 EPS.

A number of other brokerages have also recently commented on CPH. Stifel Canada raised Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 12th. Stifel Nicolaus lowered their price target on shares of Cipher Pharmaceuticals from C$19.00 to C$17.00 in a report on Monday.

Cipher Pharmaceuticals Stock Down 7.9 %

CPH opened at C$12.79 on Monday. Cipher Pharmaceuticals has a 12 month low of C$5.03 and a 12 month high of C$19.69. The company has a current ratio of 11.18, a quick ratio of 2.67 and a debt-to-equity ratio of 0.33. The business’s 50-day moving average price is C$16.07 and its 200-day moving average price is C$12.30. The company has a market cap of C$327.30 million, a P/E ratio of 10.23 and a beta of 1.20.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last issued its earnings results on Thursday, November 7th. The company reported C$0.01 EPS for the quarter, missing analysts’ consensus estimates of C$0.03 by C($0.02). Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%. The business had revenue of C$14.15 million during the quarter, compared to analysts’ expectations of C$13.37 million.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.